Quality of Life and Survival Outcomes of Metastatic Prostate Cancer Patients Treated with Prostate Directed Radiotherapy

Evaluating the Outcomes and Tolerability of Adding Local Radical Prostate Radiotherapy to the Standard of Care in Metastatic Prostate Cancer Patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

PACTR

Registry ID

PACTR202305854600529

Enrollment

Registered

2023-05-22

Start date

2020-11-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Interventions

Radical local prostate radiotherapy

Standard of care androgen deprivation therapy

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Patients diagnosed with metastatic prostate cancer who were receiving standard of care, androgen deprivation therapy and were: • Patients scored performance status 0-2 according to Eastern Cooperative Oncology Group (ECOG) performance scale. • Histologically proven adenocarcinoma of the prostate. • De-novo (synchronous) and metachronous metastatic prostate cancer patients. • Low volume metastatic prostate cancer (< 4 bone metastases) according to CHAARTED definition. • High-volume metastatic prostate cancer (= 4 bone metastases at least 1 beyond spine or pelvis, ± visceral metastases) according to CHAARETED definition. • No previous radical prostatectomy. • With or without nodal involvement. • Adequate hematological profile; Hemoglobin = 10.0 g/dl, neutrophil count =1500 cells/mm3 and platelets =100000/mL before the start of treatment. • Written informed consent.

Exclusion criteria

Exclusion criteria: Patients scored PS > 2 according to ECOG performance scale. • Presence of other diagnosed malignancies • Previous radical prostatectomy. • Previous local prostate radiotherapy or brachytherapy. • Presence of brain metastases or leptomeningeal metastases.

Design outcomes

Primary

Measure	Time frame
1. Clinical and radiological response after adding local radiotherapy to the standard of care versus standard of care only. 2. progression free survival 3. Early and late adverse events and possible toxicities after the addition of local radiotherapy to the standard treatment. 4. Patient reported Health related quality of life after radiation treatment versus the standard treatment only.	—

Secondary

Measure	Time frame
Overal survival, Clinicopathological features of metastatic prostate cancer	—

Countries

Egypt

Contacts

Public ContactEman El Semary

Lecturer of Clinical Oncology and Nuclear Medicine MD

Eman.semary87@gmail.com+2010056634

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026